Copyright
©The Author(s) 2021.
World J Cardiol. Apr 26, 2021; 13(4): 82-94
Published online Apr 26, 2021. doi: 10.4330/wjc.v13.i4.82
Published online Apr 26, 2021. doi: 10.4330/wjc.v13.i4.82
Figure 4 Forest plots comparing rivaroxaban with warfarin regarding hazard ratio of ischemic stroke, all-cause mortality, major bleeding, intracranial hemorrhage, and gastrointestinal bleeding.
HR: Hazard ratio; CI: Confidence interval.
- Citation: Li WJ, Archontakis-Barakakis P, Palaiodimos L, Kalaitzoglou D, Tzelves L, Manolopoulos A, Wang YC, Giannopoulos S, Faillace R, Kokkinidis DG. Dabigatran, rivaroxaban, and apixaban are superior to warfarin in Asian patients with non-valvular atrial fibrillation: An updated meta-analysis. World J Cardiol 2021; 13(4): 82-94
- URL: https://www.wjgnet.com/1949-8462/full/v13/i4/82.htm
- DOI: https://dx.doi.org/10.4330/wjc.v13.i4.82